Drug Therapy for Rheumatoid Arthritis in Adults
DMARDs in Rheumatoid Arthritis Treatment (2 of 2)
Oral disease-modifying anti-rheumatic drugs (DMARDs) are small-molecule chemical drugs. The mechanism of action of each of these drugs is not well defined and is unknown in some cases.
Biologic DMARDs block the activity of immunostimulatory cytokines and other cell-signaling molecules. They include genetically engineered antibodies and proteins. Tumor necrosis factor-alpha blockers are the most typical members of this drug class. Other targets are interleukins 1 and 6 and the transmembrane proteins CD20 and CD28.
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | oral | cytokines | TNF-alpha | tumor necrosis factor-alpha | interleukin 1 | IL-1 | interleukin 6 | IL-6 | CD20 | CD28
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.